RecruitingPhase 2NCT07105748

HAIC Combined With Camrelizumab Plus Rivoceranib for Advanced Mixed Hepatocellular-cholangiocarcinoma (HCC-CCA)

Studying Carcinoma of liver and intrahepatic biliary tract

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Fudan University
Intervention
Camrelizumab(drug)
Enrollment
45 enrolled
Eligibility
18 years · All sexes
Timeline
20252028

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07105748 on ClinicalTrials.gov

Other trials for Carcinoma of liver and intrahepatic biliary tract

Additional recruiting or active studies for the same condition.

See all trials for Carcinoma of liver and intrahepatic biliary tract

← Back to all trials